Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Secord

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
The Journal of Allergy and Clinical Immunology|November 1, 1996
IgE against HIV proteins in clinically healthy children with HIV diseaseE A Secord, G I Kleiner, D L Auci, et al.
Clinical and Experimental Immunology|December 24, 2010
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancersG Sinnathamby, J Zerfass, J Hafner, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|July 16, 2005
Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicinC A Hahn, E L Jones, J L Blivin, et al.
Gynecologic Oncology|July 7, 2015
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patientsKatherine C Fuh, Angeles A Secord, Kerri S Bevis, et al.
Gynecologic Oncology|April 6, 2020
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaL R Duska, G R Petroni, N Varhegyi, et al.
Gynecologic Oncology|January 8, 2017
Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinomaStuart R Pierce, Jessica E Stine, Paola A Gehrig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2011
MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancerMichael A Morse, Angeles A Secord, Kimberly Blackwell, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|July 13, 2017
Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial CancerBrittany A Davidson, Jessie Ehrisman, Sara Abbott, et al.
Gynecologic Oncology|July 27, 2017
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) studyN T Phippen, A A Secord, S Wolf, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 25, 2007
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancerJ D Wright, A A Secord, T M Numnum, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
The Journal of Allergy and Clinical Immunology|November 1, 1996
IgE against HIV proteins in clinically healthy children with HIV diseaseE A Secord, G I Kleiner, D L Auci, et al.
Clinical and Experimental Immunology|December 24, 2010
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancersG Sinnathamby, J Zerfass, J Hafner, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|July 16, 2005
Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicinC A Hahn, E L Jones, J L Blivin, et al.
Gynecologic Oncology|July 7, 2015
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patientsKatherine C Fuh, Angeles A Secord, Kerri S Bevis, et al.
Gynecologic Oncology|April 6, 2020
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaL R Duska, G R Petroni, N Varhegyi, et al.
Gynecologic Oncology|January 8, 2017
Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinomaStuart R Pierce, Jessica E Stine, Paola A Gehrig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2011
MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancerMichael A Morse, Angeles A Secord, Kimberly Blackwell, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|July 13, 2017
Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial CancerBrittany A Davidson, Jessie Ehrisman, Sara Abbott, et al.
Gynecologic Oncology|July 27, 2017
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) studyN T Phippen, A A Secord, S Wolf, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 25, 2007
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancerJ D Wright, A A Secord, T M Numnum, et al.
Pageof 5